# LOTIS 5 (NCT04384484)

> Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04384484
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ADC Therapeutics S.A.
- Conditions: Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
- Interventions: Loncastuximab Tesirine; Rituximab; Gemcitabine; Oxaliplatin
- Enrollment: 440
- Primary outcome: Progression-free Survival (PFS)

## Commentary we found

- Podcasts: 5
- YouTube: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lotis-5-nct04384484

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04384484", "email": "<work email>"}; the inbox owner confirms by the emailed link.